GlassScriptPhysician profile
Harold Davis Lewis
NPI 1689773459
$4,052.32
in general payments reported to CMS, 2019-2025
24 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,494 · 2020: $415 · 2021: $216 · 2022: $446 · 2023: $140 · 2024: $196 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $909.57 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $541.65 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $449.98 | 2019-2020 | |
| Amgen INC. | $342.23 | 2019-2024 | Otezla |
| Lilly USA, LLC | $222.56 | 2019 | |
| Astellas Pharma US INC | $178.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $135.83 | 2019-2023 | |
| Allergan, INC. | $124.48 | 2019 | |
| Esperion Therapeutics, INC. | $123.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $115.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.67 | 2019 | |
| Ironwood Pharmaceuticals, INC | $113.59 | 2025 | |
| Abbvie INC. | $111.20 | 2019 | |
| Penumbra, INC. | $102.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.59 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $70.47 | 2023 | Optimizer |
| Scilex Pharmaceuticals INC. | $64.43 | 2019 | |
| Orexo US, INC. | $56.91 | 2019 | |
| Exact Sciences Corporation | $46.65 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.66 | 2019 | |
| Kaleo, INC. | $40.27 | 2019 | |
| Celgene Corporation | $27.87 | 2019 | |
| Abbott Laboratories | $16.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.